STP1051

    FDA Enforcement in Bioprocessing Facilities

    Published: Jan 1990


      Format Pages Price  
    PDF (100K) 6 $25   ADD TO CART
    Complete Source PDF (2.3M) 6 $55   ADD TO CART


    Abstract

    Biotechnology is a rapidly developing field. Concerns for the health and safety of workers, for the safety and efficacy of the biotechnically derived products, and for potential environmental contamination have been expressed. With the development of a consistent government-wide policy for the regulation of products derived from new biotechnologies, the United States government has taken steps at agency and interagency levels to dispel these concerns. Under the authority of the Food, Drug, and Cosmetic Act of 1938, the U.S. Food and Drug Administration (FDA) evaluates and regulates the safety of biotechnology-derived products in the same way that it does for conventionally manufactured products. Scientific, safety, and regulatory issues are considered prior to approval for commercial production. Once a product receives approval, enforcement of the laws and regulations at the manufacturing level is accomplished by FDA's field personnel. The individual firm's manufacturing and quality control procedures are reviewed and evaluated to determine if they are in compliance with the Current Good Manufacturing Practice regulations. The FDA believes the current laws provide adequate regulatory protection and are sufficiently comprehensive to regulate products regardless of whether they are manufactured by traditional processes or are the products of biotechnology.

    Keywords:

    bioprocessing, biotechnology, enforcement, genetic engineering, inspection, safety, recombinant DNA, regulations


    Author Information:

    Smith, B-H
    Director of investigations, U.S. Food and Drug Administration, Chicago, IL


    Paper ID: STP26079S

    Committee/Subcommittee: E48.01

    DOI: 10.1520/STP26079S


    CrossRef ASTM International is a member of CrossRef.